687 related articles for article (PubMed ID: 14761190)
1. Recognition of privileged structures by G-protein coupled receptors.
Bondensgaard K; Ankersen M; Thøgersen H; Hansen BS; Wulff BS; Bywater RP
J Med Chem; 2004 Feb; 47(4):888-99. PubMed ID: 14761190
[TBL] [Abstract][Full Text] [Related]
2. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
3. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design.
Gloriam DE; Foord SM; Blaney FE; Garland SL
J Med Chem; 2009 Jul; 52(14):4429-42. PubMed ID: 19537715
[TBL] [Abstract][Full Text] [Related]
4. Relaxin-3, INSL5, and their receptors.
Liu C; Lovenberg TW
Results Probl Cell Differ; 2008; 46():213-37. PubMed ID: 18236022
[TBL] [Abstract][Full Text] [Related]
5. Are target-family-privileged substructures truly privileged?
Schnur DM; Hermsmeier MA; Tebben AJ
J Med Chem; 2006 Mar; 49(6):2000-9. PubMed ID: 16539387
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function.
Kristiansen K
Pharmacol Ther; 2004 Jul; 103(1):21-80. PubMed ID: 15251227
[TBL] [Abstract][Full Text] [Related]
7. Drug design strategies for targeting G-protein-coupled receptors.
Klabunde T; Hessler G
Chembiochem; 2002 Oct; 3(10):928-44. PubMed ID: 12362358
[TBL] [Abstract][Full Text] [Related]
8. Rough set-based proteochemometrics modeling of G-protein-coupled receptor-ligand interactions.
Strömbergsson H; Prusis P; Midelfart H; Lapinsh M; Wikberg JE; Komorowski J
Proteins; 2006 Apr; 63(1):24-34. PubMed ID: 16435365
[TBL] [Abstract][Full Text] [Related]
9. Activation of the ghrelin receptor is described by a privileged collective motion: a model for constitutive and agonist-induced activation of a sub-class A G-protein coupled receptor (GPCR).
Floquet N; M'Kadmi C; Perahia D; Gagne D; Bergé G; Marie J; Banères JL; Galleyrand JC; Fehrentz JA; Martinez J
J Mol Biol; 2010 Jan; 395(4):769-84. PubMed ID: 19782690
[TBL] [Abstract][Full Text] [Related]
10. An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application.
Kratochwil NA; Malherbe P; Lindemann L; Ebeling M; Hoener MC; Mühlemann A; Porter RH; Stahl M; Gerber PR
J Chem Inf Model; 2005; 45(5):1324-36. PubMed ID: 16180909
[TBL] [Abstract][Full Text] [Related]
11. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
Bhattacharya S; Hall SE; Vaidehi N
J Mol Biol; 2008 Oct; 382(2):539-55. PubMed ID: 18638482
[TBL] [Abstract][Full Text] [Related]
12. From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling.
Guba W; Green LG; Martin RE; Roche O; Kratochwil N; Mauser H; Bissantz C; Christ A; Stahl M
J Med Chem; 2007 Dec; 50(25):6295-8. PubMed ID: 18020391
[TBL] [Abstract][Full Text] [Related]
13. Virtual screen for ligands of orphan G protein-coupled receptors.
Bock JR; Gough DA
J Chem Inf Model; 2005; 45(5):1402-14. PubMed ID: 16180917
[TBL] [Abstract][Full Text] [Related]
14. Structure-based identification of binding sites, native ligands and potential inhibitors for G-protein coupled receptors.
Cavasotto CN; Orry AJ; Abagyan RA
Proteins; 2003 May; 51(3):423-33. PubMed ID: 12696053
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of automated in silico ligand docking of amino acid ligands to Family C G-protein coupled receptors.
Wang M; Hampson DR
Bioorg Med Chem; 2006 Mar; 14(6):2032-9. PubMed ID: 16297630
[TBL] [Abstract][Full Text] [Related]
16. Recognition of GPCRs by peptide ligands and membrane compartments theory: structural studies of endogenous peptide hormones in membrane environment.
Sankararamakrishnan R
Biosci Rep; 2006 Apr; 26(2):131-58. PubMed ID: 16773462
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
Huber T; Menon S; Sakmar TP
Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
[TBL] [Abstract][Full Text] [Related]
18. Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.
Fleck BA; Chen C; Yang W; Huntley R; Markison S; Nickolls SA; Foster AC; Hoare SR
Biochemistry; 2005 Nov; 44(44):14494-508. PubMed ID: 16262250
[TBL] [Abstract][Full Text] [Related]
19. Model structures of the N-methyl-D-aspartate receptor subunit NR1 explain the molecular recognition of agonist and antagonist ligands.
Moretti L; Pentikäinen OT; Settimo L; Johnson MS
J Struct Biol; 2004 Mar; 145(3):205-15. PubMed ID: 14960371
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a novel protein-ligand fingerprint to mine chemogenomic space: application to G protein-coupled receptors and their ligands.
Weill N; Rognan D
J Chem Inf Model; 2009 Apr; 49(4):1049-62. PubMed ID: 19301874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
